Summary

Persistence Market Research has recently released a comprehensive analysis of the global CMO/CDMO (Contract Manufacturing Organization/Contract Development and Manufacturing Organization) biotechnology market. This report offers a detailed evaluation of the key market dynamics, including growth drivers, trends, opportunities, and challenges, providing an in-depth understanding of the market landscape.

Key Insights:

• CMO/CDMO Biotechnology Market Size (2024E): USD 23.1 Bn
• Projected Market Value (2033F): USD 33.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 5.5%

CMO/CDMO Biotechnology Market - Report Scope:

The CMO/CDMO biotechnology market is a vital segment of the biopharmaceutical industry, focusing on the outsourcing of manufacturing and development services for biotech products. It encompasses a broad range of services, including drug development, manufacturing, and commercialization, offered by specialized organizations to biopharma companies. The market plays a significant role in accelerating drug development timelines, reducing operational costs, and enhancing manufacturing capabilities. The expansion of this market is driven by the increasing demand for biotech therapies, the growing complexity of drug development, and the need for flexible and scalable manufacturing solutions.

Market Growth Drivers:

Several factors are propelling the growth of the CMO/CDMO biotechnology market, including the rising demand for biologics and personalized medicine. Biopharma companies are increasingly outsourcing manufacturing to CMO/CDMO providers to leverage their specialized expertise, advanced technologies, and cost efficiencies. The shift towards biologics and complex drugs, coupled with the need for rapid market entry and flexibility, is driving the sector's growth. Additionally, the increasing prevalence of chronic diseases and a growing focus on novel drug therapies contribute to the rising demand for outsourced biotech manufacturing services.

Market Restraints:

Despite its growth potential, the CMO/CDMO biotechnology market faces several challenges, including regulatory complexities, intellectual property concerns, and high competition. Navigating the regulatory landscape for biotech products requires adherence to stringent standards, which can be challenging for CMO/CDMO providers. Intellectual property issues related to drug formulations and processes may also pose risks. Furthermore, the market is highly competitive, with numerous players competing for contracts, impacting pricing and profit margins.

Market Opportunities:

The CMO/CDMO biotechnology market presents significant growth opportunities driven by technological advancements, increasing investments in biopharma, and expanding therapeutic areas. Innovations in biomanufacturing technologies, such as single-use systems and continuous manufacturing, provide opportunities for market players to enhance efficiency and reduce costs. The rise of biologics and gene therapies opens new avenues for CMO/CDMO providers to cater to niche segments and develop specialized services. Strategic collaborations between CMO/CDMO firms and biopharma companies can also drive market growth and foster innovation.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the CMO/CDMO biotechnology market globally?
• Which CMO/CDMO services and therapeutic areas are experiencing significant demand?
• How are technological advancements reshaping the competitive landscape of the CMO/CDMO market?
• Who are the key players in the CMO/CDMO biotechnology market, and what strategies are they employing to maintain a competitive edge?
• What are the emerging trends and future prospects in the global CMO/CDMO biotechnology market?

Competitive Intelligence and Business Strategy:

Leading players in the global CMO/CDMO biotechnology market, such as Lonza Group, Catalent, and Samsung Biologics, are focusing on innovation, service differentiation, and strategic partnerships to strengthen their market position. These companies invest in advanced manufacturing technologies, expand their service offerings, and form alliances with biopharma firms to enhance their competitive edge. Emphasizing operational excellence, regulatory compliance, and customer-centric solutions is essential for maintaining market relevance and driving growth in the highly competitive CMO/CDMO sector.

Key Companies Profiled:

• Patheon N.V.
• Catalent
• Samsung Biologics Co., Ltd
• Lonza.
• Boehringer Ingelheim
• Samsung BioLogics
• AGC Biologics, Inc.
• WuXi Biologics
• AbbVie Inc
• Avid Bioservices, Inc.
• Fujifilm Diosynth Biotechnologies
• Xpress Biologic
• Rentschler Biopharma SE
• KBI Biopharma (JSR Corporation)
• Cytovance Biologics

Key Segments Covered in CMO/CDMO Biotechnology Industry Research

By Service:

• Stand-Alone Services
• Integrated

By Product:

• Monoclonal Antibodies
• Antibody Fragments
• Recombinant Therapeutic Proteins
• Viral Vector
• Cell and Gene Therapy
• Vaccine

By Expression System:

• Mammalian
• Microbial
• Bacteria
• Yeast

By Company Size:

• Small
• Mid-Sized
• Large
• Very Large

By Scale of Operations:

• Pre-clinical
• Clinical
• Commercial

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Service Adoption Analysis
4.2. Key Regulations
4.3. Key promotional Strategies, By Key Players
4.4. PESTEL Analysis
4.5. Service Pricing Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global CMO/CDMO Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase in R&D Spending
5.2.2. Growing Lifestyle Disease Prevalence
5.2.3. Cost of Services
5.2.4. Service Adoption Rate
5.2.5. Advancements in Technology
5.2.6. Changes in Regulatory Policies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Services
6.1.2. By Product
6.1.3. By Expression Systems
6.1.4. By Company Size
6.1.5. By Scale of Operations
6.1.6. By Country
6.2. 2024 Market Scenario
7. Global CMO/CDMO Biotechnology Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Services
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Services, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Services, 2024-2033
8.3.1. Stand-Alone Services
8.3.1.1. Cell Line Development
8.3.1.2. Development and Bio Manufacturing
8.3.1.3. Analytical Services
8.3.1.4. Fill finish
8.3.1.5. Packaging
8.3.1.6. Clinical Supply Services
8.3.2. Integrated
8.4. Market Attractiveness Analysis By Services
9. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
9.3.1. Monoclonal Antibodies
9.3.2. Antibody Fragments
9.3.3. Recombinant Therapeutic Proteins
9.3.4. Viral Vector
9.3.5. Cell and Gene Therapy
9.3.6. Vaccine
9.4. Market Attractiveness Analysis By Product
10. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Expression Systems
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Expression Systems, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Expression Systems, 2024-2033
10.3.1. Mammalian
10.3.2. Microbial
10.3.2.1. Bacteria
10.3.2.2. Yeast
10.4. Market Attractiveness Analysis By Expression Systems
11. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Company Size
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Company Size, 2024-2033
11.3.1. Small
11.3.2. Mid-sized
11.3.3. Large
11.3.4. Very large
11.4. Market Attractiveness Analysis By Company Size
12. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Scale of Operation
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019-2023
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Scale of Operation, 2024-2033
12.3.1. Preclinical
12.3.2. Clinical
12.3.3. Commercial
12.4. Market Attractiveness Analysis By Scale of Operation
13. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Region
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
14.3.1. By Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. By Services
14.3.3. By Product
14.3.4. By Expression Systems
14.3.5. By Company Size
14.3.6. By Scale of Operation
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Services
14.4.3. By Product
14.4.4. By Expression Systems
14.4.5. By Company Size
14.4.6. By Scale of Operation
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
14.8.1. U.S. CMO/CDMO Biotechnology Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Services
14.8.1.2.2. By Product
14.8.1.2.3. By Expression Systems
14.8.1.2.4. By Company Size
14.8.1.2.5. By Scale of Operation
14.8.2. Canada CMO/CDMO Biotechnology Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Services
14.8.2.2.2. By Product
14.8.2.2.3. By Expression Systems
14.8.2.2.4. By Company Size
14.8.2.2.5. By Scale of Operation
15. Latin America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Services
15.3.3. By Product
15.3.4. By Expression Systems
15.3.5. By Company Size
15.3.6. By Scale of Operation
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Services
15.4.3. By Product
15.4.4. By Expression Systems
15.4.5. By Company Size
15.4.6. By Scale of Operation
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
15.8.1. Mexico CMO/CDMO Biotechnology Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Services
15.8.1.2.2. By Product
15.8.1.2.3. By Expression Systems
15.8.1.2.4. By Company Size
15.8.1.2.5. By Scale of Operation
15.8.2. Brazil CMO/CDMO Biotechnology Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Services
15.8.2.2.2. By Product
15.8.2.2.3. By Expression Systems
15.8.2.2.4. By Company Size
15.8.2.2.5. By Scale of Operation
15.8.3. Argentina CMO/CDMO Biotechnology Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Services
15.8.3.2.2. By Product
15.8.3.2.3. By Expression Systems
15.8.3.2.4. By Company Size
15.8.3.2.5. By Scale of Operation
16. Europe CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. U.K.
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. By Services
16.3.3. By Product
16.3.4. By Expression Systems
16.3.5. By Company Size
16.3.6. By Scale of Operation
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Services
16.4.3. By Product
16.4.4. By Expression Systems
16.4.5. By Company Size
16.4.6. By Scale of Operation
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
16.8.1. Germany CMO/CDMO Biotechnology Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Services
16.8.1.2.2. By Product
16.8.1.2.3. By Expression Systems
16.8.1.2.4. By Company Size
16.8.1.2.5. By Scale of Operation
16.8.2. Italy CMO/CDMO Biotechnology Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Services
16.8.2.2.2. By Product
16.8.2.2.3. By Expression Systems
16.8.2.2.4. By Company Size
16.8.2.2.5. By Scale of Operation
16.8.3. France CMO/CDMO Biotechnology Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Services
16.8.3.2.2. By Product
16.8.3.2.3. By Expression Systems
16.8.3.2.4. By Company Size
16.8.3.2.5. By Scale of Operation
16.8.4. U.K. CMO/CDMO Biotechnology Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Services
16.8.4.2.2. By Product
16.8.4.2.3. By Expression Systems
16.8.4.2.4. By Company Size
16.8.4.2.5. By Scale of Operation
16.8.5. Spain CMO/CDMO Biotechnology Market Analysis
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Services
16.8.5.2.2. By Product
16.8.5.2.3. By Expression Systems
16.8.5.2.4. By Company Size
16.8.5.2.5. By Scale of Operation
16.8.6. BENELUX CMO/CDMO Biotechnology Market Analysis
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Services
16.8.6.2.2. By Product
16.8.6.2.3. By Expression Systems
16.8.6.2.4. By Company Size
16.8.6.2.5. By Scale of Operation
16.8.7. Russia CMO/CDMO Biotechnology Market Analysis
16.8.7.1. Introduction
16.8.7.2. Market Analysis and Forecast by Market Taxonomy
16.8.7.2.1. By Services
16.8.7.2.2. By Product
16.8.7.2.3. By Expression Systems
16.8.7.2.4. By Company Size
16.8.7.2.5. By Scale of Operation
17. East Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Services
17.3.3. By Product
17.3.4. By Expression Systems
17.3.5. By Company Size
17.3.6. By Scale of Operation
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Services
17.4.3. By Product
17.4.4. By Expression Systems
17.4.5. By Company Size
17.4.6. By Scale of Operation
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
17.8.1. China CMO/CDMO Biotechnology Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Services
17.8.1.2.2. By Product
17.8.1.2.3. By Expression Systems
17.8.1.2.4. By Company Size
17.8.1.2.5. By Scale of Operation
17.8.2. Japan CMO/CDMO Biotechnology Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Services
17.8.2.2.2. By Product
17.8.2.2.3. By Expression Systems
17.8.2.2.4. By Company Size
17.8.2.2.5. By Scale of Operation
17.8.3. South Korea CMO/CDMO Biotechnology Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Services
17.8.3.2.2. By Product
17.8.3.2.3. By Expression Systems
17.8.3.2.4. By Company Size
17.8.3.2.5. By Scale of Operation
18. South Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Malaysia
18.3.1.4. Thailand
18.3.1.5. Rest of South Asia
18.3.2. By Services
18.3.3. By Product
18.3.4. By Expression Systems
18.3.5. By Company Size
18.3.6. By Scale of Operation
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Services
18.4.3. By Product
18.4.4. By Expression Systems
18.4.5. By Company Size
18.4.6. By Scale of Operation
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Key Players - Intensity Mapping
18.8. Country Level Analysis & Forecast
18.8.1. India CMO/CDMO Biotechnology Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Services
18.8.1.2.2. By Product
18.8.1.2.3. By Expression Systems
18.8.1.2.4. By Company Size
18.8.1.2.5. By Scale of Operation
18.8.2. Indonesia CMO/CDMO Biotechnology Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Services
18.8.2.2.2. By Product
18.8.2.2.3. By Expression Systems
18.8.2.2.4. By Company Size
18.8.2.2.5. By Scale of Operation
18.8.3. Malaysia CMO/CDMO Biotechnology Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Services
18.8.3.2.2. By Product
18.8.3.2.3. By Expression Systems
18.8.3.2.4. By Company Size
18.8.3.2.5. By Scale of Operation
18.8.4. Thailand CMO/CDMO Biotechnology Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Services
18.8.4.2.2. By Product
18.8.4.2.3. By Expression Systems
18.8.4.2.4. By Company Size
18.8.4.2.5. By Scale of Operation
19. Oceania CMO/CDMO Biotechnology Market 2019-2023 and Forecast 2024-2033
19.1. Introduction
19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Services
19.3.3. By Product
19.3.4. By Expression Systems
19.3.5. By Company Size
19.3.6. By Scale of Operation
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Services
19.4.3. By Product
19.4.4. By Expression Systems
19.4.5. By Company Size
19.4.6. By Scale of Operation
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Key Players - Intensity Mapping
19.8. Country Level Analysis & Forecast
19.8.1. Australia CMO/CDMO Biotechnology Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Services
19.8.1.2.2. By Product
19.8.1.2.3. By Expression Systems
19.8.1.2.4. By Company Size
19.8.1.2.5. By Scale of Operation
19.8.2. New Zealand CMO/CDMO Biotechnology Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Services
19.8.2.2.2. By Product
19.8.2.2.3. By Expression Systems
19.8.2.2.4. By Company Size
19.8.2.2.5. By Scale of Operation
20. Middle East and Africa (MEA) CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033
20.1. Introduction
20.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
20.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Turkey
20.3.1.3. North Africa
20.3.1.4. South Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Services
20.3.3. By Product
20.3.4. By Expression Systems
20.3.5. By Company Size
20.3.6. By Scale of Operation
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Services
20.4.3. By Product
20.4.4. By Expression Systems
20.4.5. By Company Size
20.4.6. By Scale of Operation
20.5. Market Trends
20.6. Drivers and Restraints - Impact Analysis
20.7. Key Players - Intensity Mapping
20.8. Country Level Analysis & Forecast
20.8.1. GCC Countries CMO/CDMO Biotechnology Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Services
20.8.1.2.2. By Product
20.8.1.2.3. By Expression Systems
20.8.1.2.4. By Company Size
20.8.1.2.5. By Scale of Operation
20.8.2. Turkey CMO/CDMO Biotechnology Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Services
20.8.2.2.2. By Product
20.8.2.2.3. By Expression Systems
20.8.2.2.4. By Company Size
20.8.2.2.5. By Scale of Operation
20.8.3. South Africa CMO/CDMO Biotechnology Market Analysis
20.8.3.1. Introduction
20.8.3.2. Market Analysis and Forecast by Market Taxonomy
20.8.3.2.1. By Services
20.8.3.2.2. By Product
20.8.3.2.3. By Expression Systems
20.8.3.2.4. By Company Size
20.8.3.2.5. By Scale of Operation
20.8.4. North Africa CMO/CDMO Biotechnology Market Analysis
20.8.4.1. Introduction
20.8.4.2. Market Analysis and Forecast by Market Taxonomy
20.8.4.2.1. By Services
20.8.4.2.2. By Product
20.8.4.2.3. By Expression Systems
20.8.4.2.4. By Company Size
20.8.4.2.5. By Scale of Operation
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Deep Dive
22.2.1. Patheon N.V.
22.2.1.1. Overview
22.2.1.2. Service/Product Portfolio
22.2.1.3. Sales Footprint
22.2.1.4. Key Financials
22.2.1.5. SWOT Analysis
22.2.1.6. Strategy Overview
22.2.1.6.1. Marketing Strategy
22.2.1.6.2. Service Strategy
22.2.1.6.3. Channel Strategy
22.2.2. Catalent
22.2.2.1. Overview
22.2.2.2. Service/Product Portfolio
22.2.2.3. Sales Footprint
22.2.2.4. Key Financials
22.2.2.5. SWOT Analysis
22.2.2.6. Strategy Overview
22.2.2.6.1. Marketing Strategy
22.2.2.6.2. Service Strategy
22.2.2.6.3. Channel Strategy
22.2.3. Samsung Biologics Co., Ltd
22.2.3.1. Overview
22.2.3.2. Service/Product Portfolio
22.2.3.3. Sales Footprint
22.2.3.4. Key Financials
22.2.3.5. SWOT Analysis
22.2.3.6. Strategy Overview
22.2.3.6.1. Marketing Strategy
22.2.3.6.2. Service Strategy
22.2.3.6.3. Channel Strategy
22.2.4. Lonza.
22.2.4.1. Overview
22.2.4.2. Service/Product Portfolio
22.2.4.3. Sales Footprint
22.2.4.4. Key Financials
22.2.4.5. SWOT Analysis
22.2.4.6. Strategy Overview
22.2.4.6.1. Marketing Strategy
22.2.4.6.2. Service Strategy
22.2.4.6.3. Channel Strategy
22.2.5. Boehringer Ingelheim
22.2.5.1. Overview
22.2.5.2. Service/Product Portfolio
22.2.5.3. Sales Footprint
22.2.5.4. Key Financials
22.2.5.5. SWOT Analysis
22.2.5.6. Strategy Overview
22.2.5.6.1. Marketing Strategy
22.2.5.6.2. Service Strategy
22.2.5.6.3. Channel Strategy
22.2.6. Samsung BioLogics
22.2.6.1. Overview
22.2.6.2. Service/Product Portfolio
22.2.6.3. Sales Footprint
22.2.6.4. Key Financials
22.2.6.5. SWOT Analysis
22.2.6.6. Strategy Overview
22.2.6.6.1. Marketing Strategy
22.2.6.6.2. Service Strategy
22.2.6.6.3. Channel Strategy
22.2.7. AGC Biologics, Inc.
22.2.7.1. Overview
22.2.7.2. Service/Product Portfolio
22.2.7.3. Sales Footprint
22.2.7.4. Key Financials
22.2.7.5. SWOT Analysis
22.2.7.6. Strategy Overview
22.2.7.6.1. Marketing Strategy
22.2.7.6.2. Service Strategy
22.2.7.6.3. Channel Strategy
22.2.8. WuXi Biologics
22.2.8.1. Overview
22.2.8.2. Service/Product Portfolio
22.2.8.3. Sales Footprint
22.2.8.4. Key Financials
22.2.8.5. SWOT Analysis
22.2.8.6. Strategy Overview
22.2.8.6.1. Marketing Strategy
22.2.8.6.2. Service Strategy
22.2.8.6.3. Channel Strategy
22.2.9. AbbVie Inc
22.2.9.1. Overview
22.2.9.2. Service/Product Portfolio
22.2.9.3. Sales Footprint
22.2.9.4. Key Financials
22.2.9.5. SWOT Analysis
22.2.9.6. Strategy Overview
22.2.9.6.1. Marketing Strategy
22.2.9.6.2. Service Strategy
22.2.9.6.3. Channel Strategy
22.2.10. Avid Bioservices, Inc.
22.2.10.1. Overview
22.2.10.2. Service/Product Portfolio
22.2.10.3. Sales Footprint
22.2.10.4. Key Financials
22.2.10.5. SWOT Analysis
22.2.10.6. Strategy Overview
22.2.10.6.1. Marketing Strategy
22.2.10.6.2. Service Strategy
22.2.10.6.3. Channel Strategy
22.2.11. Fujifilm Diosynth Biotechnologies
22.2.11.1. Overview
22.2.11.2. Service/Product Portfolio
22.2.11.3. Sales Footprint
22.2.11.4. Key Financials
22.2.11.5. SWOT Analysis
22.2.11.6. Strategy Overview
22.2.11.6.1. Marketing Strategy
22.2.11.6.2. Service Strategy
22.2.11.6.3. Channel Strategy
22.2.12. Xpress Biologic
22.2.12.1. Overview
22.2.12.2. Service/Product Portfolio
22.2.12.3. Sales Footprint
22.2.12.4. Key Financials
22.2.12.5. SWOT Analysis
22.2.12.6. Strategy Overview
22.2.12.6.1. Marketing Strategy
22.2.12.6.2. Service Strategy
22.2.12.6.3. Channel Strategy
22.2.13. Rentschler Biopharma SE
22.2.13.1. Overview
22.2.13.2. Service/Product Portfolio
22.2.13.3. Sales Footprint
22.2.13.4. Key Financials
22.2.13.5. SWOT Analysis
22.2.13.6. Strategy Overview
22.2.13.6.1. Marketing Strategy
22.2.13.6.2. Service Strategy
22.2.13.6.3. Channel Strategy
22.2.14. KBI Biopharma (JSR Corporation)
22.2.14.1. Overview
22.2.14.2. Service/Product Portfolio
22.2.14.3. Sales Footprint
22.2.14.4. Key Financials
22.2.14.5. SWOT Analysis
22.2.14.6. Strategy Overview
22.2.14.6.1. Marketing Strategy
22.2.14.6.2. Service Strategy
22.2.14.6.3. Channel Strategy
22.2.15. Cytovance Biologics
22.2.15.1. Overview
22.2.15.2. Service/Product Portfolio
22.2.15.3. Sales Footprint
22.2.15.4. Key Financials
22.2.15.5. SWOT Analysis
22.2.15.6. Strategy Overview
22.2.15.6.1. Marketing Strategy
22.2.15.6.2. Service Strategy
22.2.15.6.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology